These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 1685443)

  • 41. Hepatocarcinogenesis by peroxisome proliferators.
    Suga T
    J Toxicol Sci; 2004 Feb; 29(1):1-12. PubMed ID: 15018150
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Induction of altered hepatic foci in rats by the administration of hypolipidemic peroxisome proliferators alone or following a single dose of diethylnitrosamine.
    Glauert HP; Beer D; Rao MS; Schwarz M; Xu YD; Goldsworthy TL; Coloma J; Pitot HC
    Cancer Res; 1986 Sep; 46(9):4601-6. PubMed ID: 2873887
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The potential role of chemically induced hyperplasia in the carcinogenic activity of the hypolipidemic carcinogens.
    Butterworth BE; Loury DJ; Smith-Oliver T; Cattley RC
    Toxicol Ind Health; 1987 Jun; 3(2):129-49. PubMed ID: 3303446
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Hypolipidaemic hepatic peroxisome proliferators form a novel class of chemical carcinogens.
    Reddy JK; Azarnoff DL; Hignite CE
    Nature; 1980 Jan; 283(5745):397-8. PubMed ID: 6766207
    [No Abstract]   [Full Text] [Related]  

  • 45. Accelerated regression of carcinogen-induced preneoplastic hepatocyte foci by peroxisome proliferators, BR931, 4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio (N-B-hydroxyethyl)acetamide, and di-(2-ethylhexyl)phthalate.
    Perera MI; Shinozuka H
    Carcinogenesis; 1984 Sep; 5(9):1193-8. PubMed ID: 6147206
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Dietary glycine prevents increases in hepatocyte proliferation caused by the peroxisome proliferator WY-14,643.
    Rose ML; Germolec D; Arteel GE; Schoonhoven R; Thurman RG
    Chem Res Toxicol; 1997 Oct; 10(10):1198-204. PubMed ID: 9348444
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Carcinogenesis by hepatic peroxisome proliferators: evaluation of the risk of hypolipidemic drugs and industrial plasticizers to humans.
    Reddy JK; Lalwai ND
    Crit Rev Toxicol; 1983; 12(1):1-58. PubMed ID: 6360536
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Differential effect of peroxisome proliferators on rat glutathione S-transferase isoenzymes.
    Voskoboinik I; Drew R; Ahokas JT
    Toxicol Lett; 1996 Oct; 87(2-3):147-55. PubMed ID: 8914623
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Mechanism of action of the nongenotoxic peroxisome proliferators: role of the peroxisome proliferator-activator receptor alpha.
    Gonzalez FJ; Peters JM; Cattley RC
    J Natl Cancer Inst; 1998 Nov; 90(22):1702-9. PubMed ID: 9827524
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clofibrate treatment in pigs: effects on parameters critical with respect to peroxisome proliferator-induced hepatocarcinogenesis in rodents.
    Luci S; Giemsa B; Hause G; Kluge H; Eder K
    BMC Pharmacol; 2007 Apr; 7():6. PubMed ID: 17437637
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Hepatomegaly is an early biomarker for hepatocarcinogenesis induced by peroxisome proliferators.
    Takagi A; Sai K; Umemura T; Hasegawa R; Kurokawa Y
    J Environ Pathol Toxicol Oncol; 1992; 11(3):145-9. PubMed ID: 1625184
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Peroxisome proliferators activate Kupffer cells in vivo.
    Bojes HK; Thurman RG
    Cancer Res; 1996 Jan; 56(1):1-4. PubMed ID: 8548746
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Role of oxidative stress in non-genotoxic carcinogenesis with special reference to liver tumors induced by peroxisome proliferators.
    Sai-Kato K; Takagi A; Umemura T; Hasegawa R; Kurokawa Y
    Biomed Environ Sci; 1995 Sep; 8(3):269-79. PubMed ID: 8561928
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Mechanistically-based human hazard assessment of peroxisome proliferator-induced hepatocarcinogenesis.
    Ashby J; Brady A; Elcombe CR; Elliott BM; Ishmael J; Odum J; Tugwood JD; Kettle S; Purchase IF
    Hum Exp Toxicol; 1994 Nov; 13 Suppl 2():S1-117. PubMed ID: 7857698
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Tumor promotion by the peroxisome proliferator nafenopin involving a specific subtype of altered foci in rat liver.
    Kraupp-Grasl B; Huber W; Putz B; Gerbracht U; Schulte-Hermann R
    Cancer Res; 1990 Jun; 50(12):3701-8. PubMed ID: 1971196
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Evidence against peroxisome proliferation-induced hepatic oxidative damage.
    Soliman MS; Cunningham ML; Morrow JD; Roberts LJ; Badr MZ
    Biochem Pharmacol; 1997 May; 53(9):1369-74. PubMed ID: 9214698
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Peroxisome proliferators: their biological and toxicological effects.
    Dzhekova-Stojkova S; Bogdanska J; Stojkova Z
    Clin Chem Lab Med; 2001 Jun; 39(6):468-74. PubMed ID: 11506454
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Peroxisome proliferation and lipid peroxidation in rat liver.
    Goel SK; Lalwani ND; Reddy JK
    Cancer Res; 1986 Mar; 46(3):1324-30. PubMed ID: 3943099
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Mitogenic effect in mouse liver induced by a hypolipidemic drug, nafenopin.
    Moody DE; Rao MS; Reddy JK
    Virchows Arch B Cell Pathol; 1977 Apr; 23(4):291-6. PubMed ID: 404752
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Rodent carcinogenicity of peroxisome proliferators and issues on human relevance.
    Lai DY
    J Environ Sci Health C Environ Carcinog Ecotoxicol Rev; 2004 May; 22(1):37-55. PubMed ID: 15845221
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.